IMMUPHARMA PLC — Share Issue/Capital Change 2022

Jun 28, 2022

National Storage Mechanism | Additional information

RNS Number : 5391Q

Immupharma PLC

28 June 2022

28 June 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

Admission of new ordinary shares of £0.01 following share capital reorganisation

At the AGM held earlier today, shareholders approved a resolution to sub-divide each existing ordinary share of £0.10 nominal value in the capital of the Company ("Existing Ordinary Shares")into one ordinary share of £0.01 each nominal value; and one deferred share of £0.09 each (these deferred shares have no voting rights, and no practical value).

Application has today been made for 284,984,933 ordinary shares of £0.01 ("New Ordinary Shares") to be admitted to trading on AIM. Admission is expected on or around Monday 4 July 2022.

The ISIN code of the New Ordinary Shares of £0.01 nominal value will remain the same (GB0033711010) as for the previous ordinary shares of £0.10 nominal value.

Following Admission each shareholders will hold the same number of New Ordinary Shares as they held of Existing Ordinary Shares.

Total Voting Rights

Following Admission, the Company's issued share capital will comprise 284,984,933 Ordinary Shares of £0.01 each with one voting right each. As the Company does not hold any shares in Treasury, the total number of voting rights in the Company is also 284,984,933 and this figure of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman and Chief Executive Officer	+44 (0) 207 206 2650
Lisa Baderoon, Head of Investor Relations & Non-Executive Director	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes, Bob Pountney SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, within our P140 platform, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of Lupus, a debilitating and potentially life threatening auto immune disease. Preclinical analysis suggests therapeutic activity for many other autoimmune diseases targeted through our P140 platform, that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDZGZVVRFGZZM